EBR Systems, the heart device hopeful heavily backed by high-profile investors, including private equity veteran Mark Carnegie and major superannuation funds, has secured approval from authorities in the United States to begin selling its technology within months.
The Food and Drug Administration approval means the company can begin generating revenues. Its wireless pacing system prevents heart failure – a market that could be worth as much as $6 billion.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。